Subscribe to RSS - home infusion therapy

home infusion therapy

Infusion providers take Medicare patients ‘case by case’

 - 
02/24/2017

YARMOUTH, Maine – One of the leading providers of home infusion therapy has stopped taking new Medicare patients and others are likely to follow suit if a “payment gap” is not closed.

In brief: Bid relief becomes official, BioScrip restructures credit

 - 
12/16/2016

WASHINGTON – President Barack Obama on Dec. 13 signed into law the 21st Century Cures Act, which offers some relief to HME providers in rural areas.

BioScrip restructures credit

 - 
12/14/2016

DENVER – BioScrip has announced a plan to increase its liquidity.

BioScrip ‘took its eye off the ball’

 - 
11/11/2016

DENVER – With revenues at BioScrip sliding again in the third quarter, new President and CEO Daniel Greenleaf didn’t mince words on a recent earnings call.

Infusion foundation launches satisfaction survey

 - 
07/13/2016

ALEXANDRIA, Va. – The National Home Infusion Foundation will launch a survey to develop a standardized set of patient satisfaction questions for home infusion providers to use in organizational assessment tools.

BioScrip completes offering

 - 
06/22/2016

DENVER – BioScrip has completed a public offering of common stock, netting approximately $83.15 million.

BioScrip makes buy, announces public offering

 - 
06/17/2016

DENVER – BioScrip, a provider of infusion and homecare management solutions, has entered into an agreement to buy the business of HS Infusion Holdings.

Outcomes prove value

 - 
01/22/2016

SAN ANTONIO – Although it may seem like a no-brainer that patients who receive infusion therapy at home fare better—and at less cost—than other patients, providers need hard data to make their case to payers, says Paul Mastrapa.

BioScrip shows progress

 - 
11/04/2015

ELMSFORD, N.Y. – BioScrip today reported third quarter revenues from continuing operations of $247.3 million, a 6.8% increase over the same period last year. Gross profit was $63.1 million, a 3.9% increase, and net loss was $24.2 million, the company reported.

Report 'rehashes' savings proposal

 - 
05/26/2015

WASHINGTON – A recent report from the Office of Inspector General that says CMS overpays for infusion drugs isn’t all that different from a similar report in 2013, say infusion stakeholders.

Pages